Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial (GlobeNewswire) - Apr 19, 2023 - "Plus Therapeutics, Inc...announced the completion of enrollment of the original three patients required in Cohort 8 of the ReSPECT-GBM Phase 1/2a dose escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of recurrent glioblastoma (GBM). Within the dose escalation phase of the trial, the Company has treated 27 patients to date."
Trial status • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
|